Literature DB >> 14738095

Inferior vena cava thrombus removal using hypothermic circulatory arrest in two patients with osteosarcoma.

Nicholas D Garcia1, Mark D Morasch, Albert D Sam, Robert L Satcher, Matthew G Blum, David A Fullerton.   

Abstract

In this case report, the technique of deep hypothermia and circulatory arrest (DHCA) is used to successfully extract extensive symptomatic tumor thrombus from the inferior vena cava (IVC) in two patients with osteosarcoma. This is the first description of the use of this modality for treatment of osteosarcoma involving the IVC. Osteosarcoma and the use of DHCA are discussed.

Entities:  

Mesh:

Year:  2003        PMID: 14738095     DOI: 10.1007/s10016-003-0077-z

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  4 in total

1.  Cardiovascular involvement by osteosarcoma: an analysis of 20 patients.

Authors:  Sireesha Yedururi; Ajaykumar C Morani; Gregory W Gladish; Srilakshmi Vallabhaneni; Peter M Anderson; Dennis Hughes; Wei-Lien Wang; Najat C Daw
Journal:  Pediatr Radiol       Date:  2015-09-28

Review 2.  Osteosarcoma tumor thrombus: a case report with a review of the literature.

Authors:  Pournima Navalkele; Sarah M Jones; Jason K Jones; Jorge D Salazar; Patrick C Toy; Rathi V Iyer; Betty Herrington
Journal:  Tex Heart Inst J       Date:  2013

3.  Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging.

Authors:  Sireesha Yedururi; Sumedha Chawla; Behrang Amini; Wei Wei; Usama I Salem; Ajaykumar C Morani; Wei-Lien Wang; Richard Gorlick; Valerae O Lewis; Najat C Daw
Journal:  Eur J Radiol       Date:  2018-05-21       Impact factor: 3.528

4.  Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma: A mono-institutional retrospective study of 115 cases.

Authors:  Haijie Liang; Wei Guo; Rongli Yang; Xiaodong Tang; Taiqiang Yan; Tao Ji; Yi Yang; Dasen Li; Lu Xie; Jie Xu
Journal:  Cancer Med       Date:  2018-08-23       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.